Wellington Management Group LLP bought a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 169,934 shares of the company's stock, valued at approximately $1,179,000. Wellington Management Group LLP owned approximately 0.26% of Evolus at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of EOLS. Nantahala Capital Management LLC purchased a new position in Evolus in the second quarter valued at about $38,878,026. BlackRock Inc. acquired a new stake in Evolus during the 2nd quarter valued at approximately $33,595,000. Braidwell LP purchased a new stake in Evolus during the 4th quarter worth approximately $20,650,000. Rice Hall James & Associates LLC purchased a new stake in Evolus during the 2nd quarter worth approximately $8,952,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Evolus in the 1st quarter valued at approximately $5,289,000. 90.69% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.00% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities analysts have recently commented on EOLS shares. Wall Street Zen upgraded Evolus from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. BTIG Research restated a "buy" rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Evolus in a report on Tuesday, August 25th. Finally, Weiss Ratings upgraded shares of Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evolus currently has a consensus rating of "Moderate Buy" and an average price target of $14.50.
Check Out Our Latest Stock Analysis on Evolus
Evolus Stock Performance
NASDAQ:EOLS opened at $7.84 on Friday. The company has a market capitalization of $517.83 million, a price-to-earnings ratio of -15.08 and a beta of 1.42. Evolus, Inc. has a one year low of $3.86 and a one year high of $9.31. The stock has a 50-day simple moving average of $7.42 and a 200 day simple moving average of $6.23.
About Evolus
(
Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Featured Articles
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
